Apotex Launches Generic Plavix
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb, Sanofi-Aventis may seek preliminary injunction against Apotex.
You may also be interested in...
Plavix Takes A Final Bow, But Will It Go Gracefully?
Generic versions of Bristol-Myers Squibb/Sanofi’s blockbuster clot-buster clopidogrel launched in the U.S. May 17, but the companies are helping some patients continue on the brand by covering the high out-of-pocket costs. Following Pfizer’s success retaining share of Lipitor, industry is paying close attention to brand retention programs.
Apotex Seeks To Maintain 156 Days Of Exclusivity For Generic Plavix
Apotex petitions FDA to stay action on other clopidogrel ANDAs, as Dr. Reddy’s gets into position for a generic launch.
Apotex Seeks To Maintain 156 Days Of Exclusivity For Generic Plavix
Apotex petitions FDA to stay action on other clopidogrel ANDAs, as Dr. Reddy’s gets into position for a generic launch.